Skip to main content
ELTX
NASDAQ Life Sciences

Elicio Therapeutics Updates Q1 Financials, Extends Runway to Q4 2026 via Dilutive ATM Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$11.39
Mkt Cap
$217.163M
52W Low
$5.15
52W High
$14.93
52W Position info
121% above low
Off High info
24% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

ELTX has more than doubled off its 52-week low of $5.15 on elevated volume (2.4× avg).

Summary

Elicio Therapeutics reported Q1 2026 financials, reiterating its 'going concern' warning and projecting a cash runway into Q4 2026, supported by $13.0 million in dilutive ATM stock sales.


Key Events · Financing and Capital Events · ELTX

  • Going Concern Warning Reiterated

    The company continues to express substantial doubt about its ability to continue as a going concern, a warning previously disclosed in its March 2026 10-K filing.

  • Short Cash Runway

    Cash and cash equivalents of $14.9 million as of March 31, 2026, are projected to fund operations only into the fourth quarter of 2026.

  • Dilutive ATM Sales Provide Short-Term Capital

    The company raised $8.0 million in Q1 2026 and an additional $5.0 million through May 8, 2026, under its At-The-Market (ATM) programs. This follows the establishment of a new $100 million ATM program in March 2026.

  • Increased Net Loss

    Reported a net loss of $11.8 million for Q1 2026, an increase from $11.2 million in Q1 2025.


Analysis · ELTX · Life Sciences

Elicio Therapeutics continues to face substantial doubt about its ability to continue as a going concern, with its cash runway now projected only into the fourth quarter of 2026. The company is actively utilizing its At-The-Market (ATM) offering, having raised $8.0 million in Q1 2026 and an additional $5.0 million through May 8, 2026. While these dilutive capital raises provide short-term liquidity, the underlying financial challenges and the need for further financing persist.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELTX was trading at $11.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.2M. The 52-week trading range was $5.15 to $14.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELTX - Latest Insights

ELTX
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.36 info
Change: -$0.045 (-3%) info
Market Cap: $37.928M info
ELTX
Nov 05, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.36 info
Change: -$0.045 (-3%) info
Market Cap: $37.928M info
ELTX
Oct 23, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.36 info
Change: -$0.420 (-24%) info
Market Cap: $37.928M info
ELTX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $1.36 info
Change: -$1.74 (-56%) info
Market Cap: $37.928M info
ELTX
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.36 info
Change: -$1.90 (-58%) info
Market Cap: $37.928M info